Intravitreal Tiue Plaminogen Activator to Treat Macular Edema Aociated With Branch Retinal Vein Occluion

Purpoe To evaluate the efficacy of intravitreal tiue plaminogen activator (tPA) injection for branch retinal vein occluion (BRVO). Deign Retropective, interventional cae erie. Method eventeen eye preenting with macular edema caued by BRVO were treated with an intravitreal tPA (Monteplae, 40 k IU) injection. We aeed the viual acuity (VA) and foveal thickne meaured with optical coherence tomography. Reult The mean duration of ymptom before urgery wa 3.6 ± 3.8 week. The mean logMAR VA ignificantly improved from 0.603 ± 0.327 at baeline to 0.388 ± 0.248 (P < .01) at one month and 0.359 ± 0.319 (P < .05) at ix month. The mean foveal thickne ignificantly decreaed from 738 ± 156 μm at baeline to 454 ± 213 μm (P < .001) at one month and 253 ± 164 μm (P < .001) ix month. Concluion Intravitreal tPA injection may be an effective treatment for reolving macular edema and improving the VA in BRVO.